Robert Kotin

Founder at Generation Bio Co.

Robert Kotin

Robert Kotin

Founder at Generation Bio Co.

Overview
Career Highlights

Generation Bio Co.

RelSci Relationships

2357

Number of Boards

1

Birthday

1956

Age

65

Relationships
RelSci Relationships are individuals Robert Kotin likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Disarm Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Generation Bio Co.

Relationship likelihood: Strong

Founder at Generation Bio Co.

Relationship likelihood: Strong

Chief Financial & Accounting Officer at Generation Bio Co.

Relationship likelihood: Strong

Executive Partner at MPM Capital Inc

Relationship likelihood: Strong

Senior Vice President & Head of Research at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Wellcome Trust Principal Research Fellow at University College - London Institute of Child Health

Relationship likelihood: Strong

Chief Executive Officer at Nimbus Apollo, Inc.

Relationship likelihood: Strong

Chief Development Officer at Obsidian Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Aeglea BioTherapeutics, Inc.

Relationship likelihood: Strong

Paths to Robert Kotin
Potential Connections via
Relationship Science
You
Robert Kotin
Founder at Generation Bio Co.
Education

The University of Medicine and Dentistry of New Jersey (UMDNJ) was a state-run health sciences institution of New Jersey, United States. It had eight distinct academic units. It formed an academic health sciences centre.

BA Biology

The University of California, Santa Cruz, has earned international distinction as a university with high-impact research and an uncommon commitment to teaching and public service. A campus with world-class facilities and one of the most visually spectacular settings in higher education, UC Santa Cruz provides unparalleled opportunities for students to learn through hands-on experience. A commitment to environmental stewardship and community engagement are also central to UCSC's core values.

PhD Microbiology

Rutgers, The State University of New Jersey, is a leading national research university and the state’s preeminent, comprehensive public institution of higher education. Rutgers is dedicated to teaching that meets the highest standards of excellence; to conducting research that breaks new ground; and to providing services, solutions, and clinical care that help individuals and the local, national, and global communities where they live. Founded in 1766, Rutgers teaches across the full educational spectrum: preschool to precollege; undergraduate to graduate; postdoctoral fellowships to residencies; and continuing education for professional and personal advancement.

Career History
Founder
2016 - Current

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Senior Investigator & Laboratory Chief
Tenure Unconfirmed

NIH is the largest source of funding for medical research in the world, creating hundreds of thousands of high-quality jobs by funding thousands of scientists in universities and research institutions in every state across America and around the globe. NIH is made up of 27 Institutes and Centers, each with a specific research agenda, often focusing on particular diseases or body systems. NIH leadership plays an active role in shaping the agency's research planning, activities, and outlook. The Office of the Director is the central office at NIH, responsible for setting policy for NIH and for planning, managing, and coordinating the programs and activities of all the NIH components. The NIH Director, with a unique and critical perspective on the entire agency, is responsible for providing leadership to the Institutes and for constantly identifying needs and opportunities, especially for efforts that involve multiple Institutes. The NIH Director is assisted by the NIH Deputy Directors including the Principal Deputy Director, who shares in the overall direction of the agency's activities. NIH is responsive to Congressional legislation that adjusts NIH's programs to meet changing research needs. As a result of the NIH reauthorization process, NIH is able to respond strategically in an era when medical research requires constant innovation and increased interdisciplinary efforts. More than 80% of the NIH's budget goes to more than 300,000 research personnel at over 2,500 universities and research institutions. In addition, about 6,000 scientists work in NIH’s own Intramural Research laboratories, most of which are on the NIH main campus in Bethesda, Maryland. The main campus is also home to the NIH Clinical Center, the largest hospital in the world totally dedicated to clinical research. Successful biomedical research depends on the talent and dedication of the scientific workforce. NIH supports many innovative training programs and funding mechanisms that foster scientific creativity and exploration. The goal is to strengthen our nation’s research capacity, broaden our research base, and inspire a passion for science in current and future generations of researchers. NIH encourages and depends on public involvement in federally supported research and activities. NIH’s wide-ranging public efforts include outreach and education, nationwide events, requests for public input on NIH projects, and special programs designed specifically to involve public representatives in clinical research

Vice President of Production
Prior - 2016

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Investments
Details Hidden

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Robert Kotin. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Robert Kotin's profile does not indicate a business or promotional relationship of any kind between RelSci and Robert Kotin.